Open-Angle Glaucoma (OAG) Market Outlook

Thelansis’s “Open-Angle Glaucoma (OAG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Open-Angle Glaucoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Open-Angle Glaucoma (OAG) Overview

Open-angle glaucoma is a chronic progressive optic neuropathy characterized by painless retinal ganglion cell degeneration and corresponding visual field loss, typically driven by impaired aqueous humor outflow despite an open anterior chamber angle. Risk factors include aging, elevated intraocular pressure, Black ethnicity, and genetic variants like MYOC or OPTN, though normal-tension variants can occur without elevated pressure. Diagnosis relies on tonometry, gonioscopy, optical coherence tomography of the retinal nerve fiber layer, and standard automated perimetry. While primary treatment relies on pressure reduction via selective laser trabeculoplasty or topical prostaglandin analogs, the management paradigm has shifted drastically to bypass daily drop adherence barriers. This includes the widespread integration of sustained-release intracameral delivery systems, such as the travoprost implant (iDose TR), which deliver continuous long-term pressure control. Furthermore, the pipeline has advanced with the formal regulatory filing of bimatoprost grenod (NCX 470), a novel dual-action nitric oxide-donating prostaglandin analog that achieved superior intraocular pressure lowering over latanoprost in the pivotal Mont Blanc and Denali trials. Advanced or refractory disease is managed with minimally invasive glaucoma surgery (MIGS) or traditional trabeculectomy. Lifelong surveillance and personalized tracking are essential to safeguard vision.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)